Please login to the form below

Not currently logged in
Email:
Password:

haemophilia

This page shows the latest haemophilia news and features for those working in and with pharma, biotech and healthcare.

Pfizer enters late-stage haemophilia B gene therapy trial

Pfizer enters late-stage haemophilia B gene therapy trial

Pfizer enters late-stage haemophilia B gene therapy trial. Race is on to free patients of regular injections. ... If all goes well for Pfizer, its therapy might free patients of regularly injecting an engineered version of clotting factor IX – which

Latest news

  • NHS England says yes to Roche's Hemlibra NHS England says yes to Roche's Hemlibra

    Roche’s new haemophilia A treatment Hemlibra has gained a valuable market access approval from NHS England. ... There are an estimated 5, 930 patients registered with Haemophilia A in the UK, of which 230 have factor VIII inhibitors.

  • UniQure’s starts pivotal haemophilia B gene therapy trial UniQure’s starts pivotal haemophilia B gene therapy trial

    UniQure’ s starts pivotal haemophilia B gene therapy trial. The treatment could relieve haemophilia B patients from factor IX replacement drugs. ... gene therapy that will deliver a gene sequence for clotting factor IX, which is deficient in

  • Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

    Yen Choo, founder and executive chairman of Plasticell. Another example of a hugely exciting pipeline gene therapy coming out of UCL is in haemophilia A, initially developed by Professor Amit Nathwani

  • The year of the blockbuster The year of the blockbuster

    The diseases targeted by the report’s projected market entrants include type 2 diabetes, endometriosis, childhood epilepsy, haemophilia, HIV, migraine, opioid addiction and shingles. ... Hemlibra (emicizumab) from Roche/Chugai:A novel approach to

  • Freeline raises £88m to accelerate haemophilia gene therapy Freeline raises £88m to accelerate haemophilia gene therapy

    Freeline raises £88m to accelerate haemophilia gene therapy. Spin-out from London university joins fast-developing field. ... peripheral blood, and already has clinical trials in hand for its first haemophilia B candidate.

More from news
Approximately 51 fully matching, plus 125 partially matching documents found.

Latest Intelligence

  • ‘How is your day?’ ‘How is your day?’

    World champion cyclist Alex Dowsett lives with severe haemophilia. He also speaks for ‘How Is Your Day? ’. ... plasma. Haemophilia is a condition that can be treated by both laboratory-produced recombinant plasma therapies or medicines made from

  • The NHS and ABPI at 70: inching closer to the triple win The NHS and ABPI at 70: inching closer to the triple win

    Meanwhile, the pharma industry is hitting new heights in drug innovation, including cures for diseases such as hepatitis C, haemophilia and huge progress in cancer and cell and gene therapy - but

  • Health on instalment Health on instalment

    years. Initial disease targets include cancer, neuromuscular disease, haemophilia, immunodeficiencies and blindness.

  • Deal Watch January 2018

    Strategically caplacizumab represented a good fit for Novo Nordisk as it complements the company's portfolio of products focused on haemophilia. ... Portfolio/pipeline in haemophilia and other rare blood disorders. Acquisition company. 11, 600.

  • The good, the bad and the ugly The good, the bad and the ugly

    However, investors fear that challenges in the $11bn haemophilia market could lead to a slump in the haemophilia business it inherited through the Baxalta purchase.

More from intelligence
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest appointments

  • Sobi appoints Torbjorn Hallberg as general counsel Sobi appoints Torbjorn Hallberg as general counsel

    Also sitting on the new team are Sobi's head of specialty care Norbert Oppitz, h ead of medical and scientific affairs Armin Reininger, h ead of haemophilia Philip Wood and

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Freeline comprises some of the world’s leading experts in gene therapy, haemophilia and other debilitating disorders and I look forward to working closely with them to demonstrate the potential of ... She has also worked at Novo Nordisk as senir vice

  • Clark Health Communications expands team Clark Health Communications expands team

    Campbell will support and assist the team across its women’s health, gastroenterology and haemophilia accounts.

  • Shire’s Dr Armin Reininger moves to Sobi Shire’s Dr Armin Reininger moves to Sobi

    global medical affairs for haemophilia. ... Armin will apply his deep experience as an industry leader and academic in haemophilia to our team, as well as his global experience in medical scientific affairs to our stakeholders.”.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics